Clinical Trial Update: ENABLE-HCM - AI-ENabled Echocardiography With Ultrasound Beyond the Echo Lab for Better HCM Imaging and Expanded Access

View source ↗

Summary

The ENABLE-HCM trial evaluating AI-enabled echocardiography for hypertrophic cardiomyopathy imaging has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy
• Obstructive Hypertrophic Cardiomyopathy

Drugs mentioned

• CAMZYOS (MAVACAMTEN)
• Mavacamten (mavacamten)

Snippet

Sponsor: UltraSight | Conditions: Hypertrophic Cardiomyopathy (HCM), Cardiac Imaging | Status: TERMINATED